Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The OsteoCool™ Post Market Clinical Study (OPuS One) is a multicenter study collecting real-world evidence on the efficacy and safety of OsteoCool™ RF ablation.
Twelve-month data show outcomes in 206 patients treated with OsteoCool™ RF ablation, as well as pain relief and improved quality of life in as soon as three days.1
The OsteoCool™ RF ablation system is cooled radiofrequency ablation technology. It offers simultaneous, dual-probe capabilities for treating painful bone tumors, including benign and painful metastatic lesions. The system’s algorithms are designed to perform optimally in bone, allowing you to overcome challenges through a wide range of ablation scenarios, letting you treat patients confidently and consistently.
Intro to OsteoCool™ RF Ablation System Animation
More information (see more) Less information (see less)
See physician videos about using OsteoCool™ RF ablation for cancer patients.
Levy J, David E, Hopkins T, et al. Improvement in Quality of Life on Patients Treated for Painful Osseous Metastases With Radiofrequency Ablation: The Opus One Study, abstract presented at Society for Interventional Radiology Annual Scientific Meeting, March 20-26, 2021, virtual. https://www.researchgate.net/publication/351170997_Abstract_No_78_Improvement_in_quality_of_life_in_patients_treated_for_painful_osseous_metastases_with_radiofrequency_ablation_the_OPuS_One_study. Accessed November 8, 2021.